ArticleJournal of the International AIDS Society2020
New opportunities in tuberculosis prevention: implications for people living with HIV.
Article in Journal of the International AIDS Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Pooled it
- TB will never end because of us: Experiences of TB preventive treatment among people living with HIV/AIDS in South Africa.PloS one · 2025Trial
- Review
- The implementation of tuberculosis preventive therapy in HIV care clinics in Africa, Asia and Latin America: a multiregional site survey.BMJ global health · 2026Article
- Analysis of the diagnostic efficacy of targeted next-generation sequencing for tuberculosis in patients with HIV.Frontiers in cellular and infection microbiology · 2026Article
- Analysis of Tuberculosis Preventive Treatment Cascade Among People With Human Immunodeficiency Virus in Georgia: A Mixed-Methods Study.Open forum infectious diseases · 2026Article
- Innovations in TB Screening and Preventive Therapy Services for PLHIV in Yogyakarta City, Indonesia.Tropical medicine and infectious disease · 2025Article
- A nomogram for predicting unfavorable outcomes of antituberculosis treatment among individuals with AIDS combined with pulmonary tuberculosis in China.Frontiers in immunology · 2025Article
- A Comprehensive Review of HIV-Associated Tuberculosis: Clinical Challenges and Advances in Management.Cureus · 2024Review
- Article
- Article
- The impact of a combined TB/HIV intervention on the incidence of TB infection among adolescents and young adults in the HPTN 071 (PopART) trial communities in Zambia and South Africa.PLOS global public health · 2023Article
- Tuberculosis preventive treatment in people living with HIV-Is the glass half empty or half full?PLoS medicine · 2021Article
- Health system determinants of tuberculosis mortality in South Africa: a causal loop model.BMC health services research · 2021Article
- Turning threats into opportunities: how to implement and advance quality TB services for people with HIV during the COVID-19 pandemic and beyond.Journal of the International AIDS Society · 2021Article
- Dynamic needs and challenges of people with drug-resistant tuberculosis and HIV in South Africa: a qualitative study.The Lancet. Global health · 2021Observational
- HIV in the Kingdom of Saudi Arabia: Can We Change the Way We Deal with Co-Infections.Infection and drug resistance · 2021Review
- Are We There Yet? Short-Course Regimens in TB and HIV: From Prevention to Treatment of Latent to XDR TB.Current HIV/AIDS reports · 2020Review
- Human immunodeficiency virus infection amongst newly diagnosed tuberculosis patients and their clinico-radiological profile: A prospective study from Western India.Journal of family medicine and primary care · 2020Article
- Characterization of the Mycobacterial MSMEG-3762/63 Efflux Pump inFrontiers in microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 11 institutions in 7 countries.
Funding
Abstract
introductionTuberculosis (TB) is a leading cause of mortality among people living with HIV (PLHIV). An invigorated global END TB Strategy seeks to increase efforts in scaling up TB preventive therapy (TPT) as a central intervention for HIV programmes in an effort to contribute to a 90% reduction in TB incidence and 95% reduction in mortality by 2035. TPT in PLHIV should be part of a comprehensive approach to reduce TB transmission, illness and death that also includes TB active case-finding and prompt, effective and timely initiation of anti-TB therapy among PLHIV. However, the use and implementation of preventive strategies has remained deplorably inadequate and today TB prevention among PLHIV has become an urgent priority globally. DISCUSSION: We present a summary of the current and novel TPT regimens, including current evidence of use with antiretroviral regimens (ART). We review challenges and opportunities to scale-up TB prevention within HIV programmes, including the use of differentiated care approaches and demand creation for effective TB/HIV services delivery. TB preventive vaccines and diagnostics, including optimal algorithms, while important topics, are outside of the focus of this commentary.
conclusionsA number of new tools and strategies to make TPT a standard of care in HIV programmes have become available. The new TPT regimens are safe and effective and can be used with current ART, with attention being paid to potential drug-drug interactions between rifamycins and some classes of antiretrovirals. More research and development is needed to optimize TPT for small children, pregnant women and drug-resistant TB (DR-TB). Effective programmatic scale-up can be supported through context-adapted demand creation strategies and the inclusion of TPT in client-centred services, such as differentiated service delivery (DSD) models. Robust collaboration between the HIV and TB programmes represents a unique opportunity to ensure that TB, a preventable and curable condition, is no longer the number one cause of death in PLHIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.